<DOC>
	<DOCNO>NCT00610389</DOCNO>
	<brief_summary>Background : cellular immunotherapy dendritic cell ( DC ) load tumor antigen show clinical activity , although small number patient . Therefore , mandatory improve result strategy closely monitor immunologic response cell migration order improve understand mechanisms action settle future field development.. Objectives : Primary : confirm clinical activity strategy , determine tumor response ( RECIST criterion ) . Secondary : determine : ( 1 ) safety ; ( 2 ) antitumoral immune response ( 3 ) DC migration organism Methodology : phase II trial patient advance renal cell carcinoma melanoma . We perform repeat immunization DC load patient´s tumor .</brief_summary>
	<brief_title>Phase II Study With Immunotherapy With Dendritic Cells Tumor Infiltrating Lymphocytes Solid Tumors</brief_title>
	<detailed_description>Background : cellular immunotherapy dendritic cell ( DC ) load tumor antigen show clinical activity , although small number patient . Therefore , mandatory improve result strategy closely monitor immunologic response cell migration order improve understand mechanisms action settle future field development.. Objectives : Primary : confirm clinical activity strategy , determine tumor response ( RECIST criterion ) . Secondary : determine : ( 1 ) safety ; ( 2 ) antitumoral immune response ( study delay hypersensitivity ; ELISPOT ; activity Natural Killer cell ; serum cytokine concentration ) ; ( 3 ) DC migration organism , label 111-Indium oxinate Methodology : phase II trial patient advance renal cell carcinoma melanoma . We perform repeat immunization mature DC load autologous tumor . We introduce follow novel element enhance efficacy ( 1 ) Pre-treatment cyclophosphamide reduce regulatory / suppressor T cell ; ( 2 ) maturation/activation DC induce TNF-alfa , IFN-alfa double strand RNA ( GMP-manufactured poly I : C ) , aim replication phenomenon observe viral infection ( 3 ) intranodal DC administration inguinal lymph node ( 4 ) four daily dos ( repeat every 24 hour ) two cycle one month apart ( 5 ) scintigraphic follow-up trace dose 111-In label DC ( 6 ) ) systemic treatment PEG-IFN alfa GM-CSF potentiate activity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Confirmed diagnosis metastatic melanoma , renal cell carcinoma , hepatocarcinoma ( Child´s stage A B ) amenable curative treatment . For patient hepatocarcinoma , treatment embolization allow Measurable disease ECOG 0 , 1 2 . Adequate renal , hepatic bone marrow function Availability tumor tissue , mature dendritic cell Clinically relevant disease infection . concurrent participation clinical trial administration antitumoral treatment Concurrent cancer , exception allow PI . Pregnant breast feeding woman immunosuppressant treatment know CNS metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>